key: cord-0946895-vqdbdef6
authors: Gniffke, E. P.; Harrington, W. E.; Dambrauskas, N.; Jiang, Y.; Trakhimets, O.; Vigdorovich, V.; Frenkel, L.; Sather, D. N.; Smith, S. E. P.
title: Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
date: 2020-06-11
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.06.09.20127050
sha: df197156181ffc932956f647d90bcacae2e42800
doc_id: 946895
cord_uid: vqdbdef6

High throughput serological tests that can establish the presence and functional activity of anti-SARS-COV2 antibodies are urgently needed. Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). First, we detected anti-trimer IgGs in 22/24 and anti-RBD IgGs in 21/24 COVID+ subjects at a median of 36 (range 14-73) days following documented SARS-CoV-2 RNA (+) secretions. Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels. Depletion of trimer-reactive Igs from plasma reduced ACE2-trimer inhibitory capacity to a greater degree than depletion of RBD-reactive Igs, suggesting that inhibitory antibodies act by binding both within and outside of the RBD. Amongst the 24 subjects, presence of fever was associated with higher levels of anti-trimer IgG and inhibition of binding to human ACE2. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.

In late 2019 a novel SARS-like coronavirus (SARS-CoV-2) emerged in Wuhan, China 1 . It rapidly spread across the globe, and the disease it causes, COVID19, was declared a pandemic by the WHO in March 2020 2 . The cryo-EM structure of the spike glycoprotein, a viral surface protein that mediates cell entry of corona viruses, was solved by two groups 3, 4 , revealing a trimeric structure with either none or one of three receptor binding domains (RBDs) in the "up" state, capable of binding to its target. Similar to the 2003 SARS-CoV-1 virus, angiotensin converting enzyme 2 (ACE2) serves as the receptor necessary and sufficient for infection of the target cell [3] [4] [5] [6] [7] .

Nearly all patients who recover from SARS-CoV-2 infection produce IgM and IgG antibodies against the spike protein [7] [8] [9] , and a large number of serologic tests have been produced and marketed. However, it is unclear how effective the detected antibodies are at neutralizing viral activity. The percentage of people who show functional responses using cellor protein-based neutralizing assays varies depending upon the analytical strategy used; for example a study measuring in vitro inhibition of ACE2-RBD binding in an ELISA-style assay showed only 3 of 26 (11.5%) recovered patients strongly inhibited binding 7 , while a larger study using pseudotyped lentivirus showed significant inhibition of infectivity in 165 of 175 (94.3%) recovered patients 9 . Indeed, human monoclonal antibodies that neutralize SARS-CoV-2 infectivity have been show to bind epitopes both within 7 and outside of the RBD 10 , so it is unclear if RBD-based measurements capture the full repertoire of inhibition of viral infectivity.

While pseudoviruses that use the native spike protein to infect cells appear to at identify antibodies that neutralize viral entry 9 , these assays are technically demanding, require specialized biosafety facilities, and may be difficult to scale up for population-level testing.

Here, we describe a novel, overnight, cell-free assay to quantify a plasma sample's ability to inhibit the binding of ACE2 to the recombinant trimeric spike protein 3 . The assay is based on immunoprecipitation detected by flow cytometry (IP-FCM) technology, a highly All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint sensitive and reagent efficient method for detecting protein-protein interactions using minimal amounts of biomaterial 11, 12 . We find that while only a minority of persons who have recovered from symptoms of COVID-19 produce antibodies that inhibit the RBD domain binding to ACE2 in vitro, almost all (22/24) produce antibodies that potently inhibit the full trimer binding to ACE2.

Our results provide a new, relatively rapid and high-throughput method to quantify circulating levels of functional anti-SARS-CoV-2 antibodies, and suggest that the entire spike protein as opposed to the RBD should be used when characterizing SARS-CoV-2 immunity.

We designed and optimized IP-FCM assays to detect the presence of anti-SARS-CoV-2 spike antibodies in human serological samples by covalently coupling either the recombinant RBD fragment 13 or a spike trimer construct 3 to carboxy-modified polystyrene latex (CML, data shown in supplemental figures) or to Luminex MagPlex microspheres. Coupled beads were then incubated with increasing dilutions of plasma specimens, and then with anti-human IgG antibodies conjugated to phycoerythrin (PE) ( Figure 1A ). Plasma specimens were obtained from participants with SARS-CoV-2 RNA (+) nasopharyngeal secretions detected by rt-PCR at ≥14+ days post-symptom onset. These participants include COVID19+ subjects, confirmed by RTPCR, enrolled into the Seattle Children's SARS2 Recovered Cohort on/by 6/1/2020. Additionally, de-identified banked plasmas from healthy individuals collected before 2019 were used as negative controls. A plasma-dilution experiment using specimens from three SARS-CoV-2 RNA (+) and two pre-2019 samples detected high levels of anti-human IgG in the positive samples, and non-specific background reactivity in the controls that decreased to near 0 at higher dilutions ( Figure S1A ,B). Note that when using IP-FCM, lower median fluorescent intensity (MFI) values at high concentrations of analyte can occur, resulting the U-shaped curve shown in Figure S1A . We chose 1:1000 as an optimal plasma dilution, and separately identified All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint 2 hours at room temperature (22-24 o C) as the incubation conditions that resulted in the best signal-to-noise ratio (data not shown).

Using MFI from the 30 control specimens, SARS-CoV-2 antibodies were stringently defined as "positive" at an MFI greater than the highest control value plus 5 standard deviations of the control values (dashed lines in Figure 1B ,C). Using this definition, 22/24 (91.6%) COVID+ samples were classified as 'seropositive' for trimer reactivity, and 21/24 (87.5%) for RBD. There was a moderate correlation between RBD and trimer immunoreactivity ( Figure 1D , r 2 = 0.64).

Experiments performed using CML microspheres during assay development using a subset of the total plasma samples showed similar results (Figure S1), and there was correlation between trimer (r 2 = 0.85) and RBD (r 2 = 0.75) values for the 12 samples that were measured using both microsphere types ( Figure S1F , G).

To determine if the presence of plasma IgG might correlate with inhibition of the virus binding to its receptor, we designed an IP-FCM assay to quantify the binding of ACE2 and SARS-CoV-2 spike protein. We coupled human ACE2 protein to CML ( Figure S2 ) or MagPlex ( Figure 2 ) microspheres and incubated with biotinylated RBD or trimer, followed by incubation with Streptavidin-PE ( Figure 2A) . Both trimer and RBD demonstrated strong binding to ACE2 ( Figure 2B ,C), and the EC50 was used to determine the dilution of spike proteins added to the binding inhibition assay. As a specificity control, unlabeled human ACE2 inhibited binding of both RBD and trimer by >90% ( Figure 2D ,E). After optimizing the plasma dilution ( Figure   S2C ,D,), we evaluated the same 24 COVID19+ and 30 pre-COVID patient plasma samples for their ability to inhibit the ACE2-Spike interaction. Analyzed as a group, the median fluorescent intensity (MFI) of control plasma was not significantly different than no-plasma controls in the trimer or RBD assays ( Figure 2F or H, respectively), while COVID+ samples significantly inhibited binding (trimer ANOVA F(2,57)=52.4, p<0.0001, COVID+ vs. no plasma and pre-COVID All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint p<0.0001 by Tukey post-hoc test; RBD ANOVA F(2,57)=5.538, p=0.006, COVID+ vs. pre-COVID p = 0.004 by Tukey post-hoc test). Similarly, when data were expressed as percent inhibition, COVID+ samples produced greater inhibition than pre-COVID for both trimer and RBD (p<0.0001 and p=0.0024, respectively, by 2-tailed t-test, Figure 2 G,I).

However, when data were examined by individual, important differences emerge between the trimer and RBD-based assays. For the trimer inhibition assay, all 22 plasma samples that tested positive for anti-trimer IgG (as defined above) showed greater inhibition than any of the negative control samples ( Figure 2J ). Conversely, in the RBD assay, only 9/24 samples showed greater inhibition than the highest negative control, despite 21/24 samples being sero-positive ( Figure 2K ). Moreover, in the trimer assay there was a strong correlation between the amount of anti-trimer IgG and the percent inhibition among COVID+ (r 2 = 0.79) but not negative control (r 2 = 0.04) samples ( Figure 2J ). There was no such correlation in the RBD assay (COVID+ r 2 = 0.047, negative control r 2 = 0.034, Figure 2K ). There was also no correlation between the percent inhibition of plasma samples in the RBD and trimer assays ( Figure 2L , COVID+ r 2 = 0.036, pre-COVID r 2 = 0.011). For the two Trimer-negative samples, follow-up testing using the commercial Cellex platform as well as laboratory-developed ELISAs using spike and nucleoprotein (n=3 different labs) failed to detected anti-SARS2 antibodies.

Experiments performed using CML microspheres during assay development using a subset of the total plasma showed similar results ( Figure S2 ). There was good correlation between trimer values for the 12 samples that were measured using both microsphere types (r 2 = 0.85, Figure S2K ), and MagPlex microspheres were more effective at distributing the population across the dynamic range of the assay. For the RBD assay, there was poor correlation between values measured using both microsphere types (r 2 = 0.15, Figure S2L ), but samples that were more effective at inhibition appeared to show a trend toward a linear relationship. Overall our data suggest that the majority of participants produces anti-trimer All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint antibodies that efficiently disrupt ACE2-trimer binding; but while most participants also produce anti-RBD antibodies, less than half also disrupt ACE2-RBD binding.

We next depleted the plasma of one negative control and three COVID+ samples by incubating plasmas with large numbers of trimer-or RBD-conjugated CML beads for three consecutive overnight incubations until the levels of IgG detected in the plasma plateaued ( Figure 3A , B). We then ran the trimer-ACE2 inhibition assay on the depleted plasma to determine if inhibition of binding was caused by antibodies binding within or outside of the RBD.

Prior to depletion, the COVID+ samples showed varying levels of ACE2-trimer binding inhibition (41-75%). Inhibition was reduced by partially (although non-significantly) reduced by RBD depletion, and was reduced to a greater degree by trimer depletion ( Figure 3C , ANOVA F(2,6)=8.51, p=0.018, Not depleted vs. RBD depleted p = 0.11, Not depleted vs. trimer depleted p = 0.015, RBD depleted vs. trimer depleted = 0.30 by Tukey post-hoc test). Thus, even though RBD depletion was more efficient than trimer depletion in terms of reduction in detectable IgG (RBD: X%, trimer Y%, Fig 3A,B) , trimer depletion was more at removing the neutralizing capacity of the plasma. These data suggest that spike trimer neutralizing antibodies bind both within and outside of the RBD.

Participants (n=24) were between 28 and 63 years of age (median 42 years of age) and were 71% (17/24) female. The day of sample collection ranged from 14 to 73 days from symptom onset, with a median of 36 days. All SARS-CoV-2 infections were symptomatic, ranging from very mild to moderate illness; no subjects required hospitalization or supplemental oxygen.

12/24 subjects experienced fever and 16/24 experienced cough. Age was associated with a trend toward increased anti-trimer IgG and inhibition (per year MFI difference: 3,816, p=0.09; All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint inhibition difference: 1%, p=0.07), although this may have been driven by the two subjects with negative IgG, who were both relatively young (28, 41). Sex, days since symptom onset, and cough were not associated with anti-trimer IgG or inhibition. In contrast, fever was strongly associated with both anti-trimer IgG and inhibition in both unadjusted (MFI difference: 103,982, p=0.007; inhibition difference: 20%, p=0.04) and adjusted models that accounted for subject age, sex, and days from symptom onset (adjusted MFI difference: 103,530, p=0.01; adjusted inhibition difference: 20%, p=0.03). Both IgG-negative subjects had very mild disease without fever.

The acquisition of antiviral immunity to SARS-CoV-2 will be a critical prerequisite for a return to normalcy from the current pandemic. As of this writing, it is still unclear if infection or vaccination will lead to robust, long-lasting immunity 14 . While some early data suggested ineffective immune responses, such as low levels of ACE2-RBD inhibition by convalescent serum in an ELISA-style binding assay 7 or the detection of viral RNA in recovered patients 15 , more recent data suggest effective anti-viral antibody activity in the majority of patients. For example, serum from 94% of recovered patients effectively inhibited pseudotyped lentiviral infection of susceptible cells 9 , similar to our rates; four Rhesus Macaques experimentally infected with SARS-CoV-2 were resistant to re-infection 16 ; and a recent report suggests that the viral RNA detected in recovered patients is not associated with an active infection or the ability to transmit COVID19 17 . Our data, demonstrating in vitro neutralization of ACE2-trimer binding in 92% of recovered patients, adds to this growing literature that collectively suggest that infection with SARS-CoV-2 results robust immunity, at least in the short-term.

While we identified robust trimer-ACE2 inhibition in IgG-positive post-convalescent plasma, only weak inhibition of RDB-ACE2 binding was detectable, and only in the minority of samples. Moreover, there was no correlation between anti-RBD levels and inhibition of ACE2-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint RBD binding, suggesting that some people may mount an antibody response to the RBD that fails to inhibit binding of the RBD construct to recombinant, bead-bound ACE2. However, this failure may be related to the relative affinity of the RBD construct to ACE2 vs. the affinity of plasma antibodies to the RBD, and thus not be relevant to in vivo immunity. Indeed, depletion of anti-RBD antibodies reduced the trimer-inhibitory activity of plasma, suggesting that at least some trimer-inhibitory antibodies bind within the RDB. This is consistent with published studies of monoclonal antibodies, which have been found to bind both within 7 and outside of 10 the RBD.

Regardless of mechanism, we report that for practical purposes, the trimer construct provides a reliable, quantitative readout of immunity while the RBD construct is less useful.

Our cohort was comprised of relatively young, healthy subjects, none of whom were hospitalized or required supplemental oxygen. Amongst these individuals, the levels of antitrimer IgG and inhibition were higher in those that experienced fever versus no fever. Findings regarding correlation between antibody levels and clinical severity have been mixed 18, 19 , with one study describing higher antibody levels in severe versus moderate COVID19 cases, all of whom were hospitalized 8 . To the best of our knowledge, this is the first description of a correlation between illness severity and antibody levels in a community cohort. Our findings may suggest that systemic illness or an inflammatory response lead to higher antibody titer; alternatively, both the presence of fever and antibody titers may reflect host intrinsic differences.

There are several limitations to our study that should be noted. First, our cases were all relatively mild (none requiring hospitalization or ventilation), and predominantly middle-aged females. Future studies comparing the responses of older or more severely ill subjects would be informative. Secondly, our study focuses solely on binding of ACE2 to the spike protein and ignores other potential antigens or other immune mechanisms such as inhibition of protease cleavage that might prevent viral entry into the cell. The results of our bead-based assay should be confirmed using a pseudovirus assay, or ideally using live SARS-CoV-2 virus. Third, it is unclear what level of inhibition would correlate with functional resistance to re-infection. Follow-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint expressed in 293F cells in antibiotic free, serum free media as previously described 20 Briefly, 250ul of MagBeads were magnetically separated using a magnetic tube rack (New All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint plasma samples were also run in parallel using BSA-coupled CML or MagBeads to determine the baseline nonspecific signal generated from each sample. For CML beads, this background varied greatly between individuals from 10 3 -10 5 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint Patient plasma was diluted 1:50 in Fly-P Buffer and incubated with 2ul of RBD-or trimercoupled CML beads overnight at 4C. The next day, the beads were pelleted at 13,000 RPM for 1 minute, removed and discarded. A 2ul aliquot of plasma was reserved, and 2ul of new, RBDor trimer-coupled CML beads were added. This process was repeated for a total of 3 overnight depletions. On the 4 th day, 25ul of the RBD-or trimer-depleted plasma was run on the ACE2trimer binding assay, as described above.

Technical replicates were averaged and data were imported to Prism 8.0 (GraphPad).

Comparisons between two groups were made using two-tailed t-tests, and among three groups with one-way ANOVA followed by post-hoc tests comparing all columns, corrected for multiple comparisons by the Tukey method. Correlations and EC50 values were determined using simple linear regressions or 4-parameter logistic regressions with default settings, and r 2 values were reported.

All parent protocols were approved by the Fred Hutchinson Cancer Research Center or Seattle Children's IRBs. This study was conducted under a protocol approved by the Seattle Children's Research Institute's IRB STUDY00002514 (SEPS). All participants signed informed consent forms.

continue during the pandemic, especially Sean Sandin and Marnie Chinn; and the recovered COVID19+ plasma donors. This study was funded by a COVID-19 research award from the University of Washington Institute for Translational Heath Sciences (via grant UL1 TR002319) and by a COVID19 award from the Research Integration Hub at Seattle Children's Research Institute (to SEPS), by an NIH/NIAID K08 AI135072 and a Burroughs Wellcome Fund CAMS 1017213 grant (to WH), and by R01 AI140951 (to DNS).

The authors declare no conflicts of interest. A provisional patent application has been filed by SCRI on the assays reported in this paper. The median fluorescent intensity of IgG measured on the trimer and RBD assays was All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint depletion, plasma was less efficient at inhibiting trimer-ACE2 binding, although the difference was not significant by ANOVA (see text for statistics). After trimer-depletion, the ability of plasma to inhibit ACE2-trimer binding was significantly reduced, with the mean overlapping with control levels. ANOVA F(2,6)=8.51, p=0.018, Not depleted vs. RBD depleted p = 0.11, ns; Not depleted vs. trimer depleted * p = 0.015; RBD depleted vs. trimer depleted = 0.30 by Tukey post-hoc test. Figure S1C ) plotted vs. anti-trimer IgG measured by the MagBead bead assay (as in Figure 1B ) for the 13 COVID+ samples measured on both assays. Solid line shows a linear regression with 95% confidence intervals indicated with dotted lines, r 2 = 0.85. (G) Anti-RBD IgG measured by the CML bead assay (as in Figure S1D ) plotted vs. anti-RBD IgG measured by the MagBead bead assay (as in Figure 1C ) for the 13 COVID+ samples measured on both assays.

Solid line shows a linear regression with 95% confidence intervals indicated with dotted lines, r 2 = 0.75. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint (C,D) Plasma from 3 COVID+ samples (red) and two controls (black) was serially diluted, and inhibition of Ace2 binding was measured using the trimer (C) or RBD (D) inhibition assay. E) Compared to a no-plasma control (blue), pre-COVID control plasma significantly inhibited Trimer-ACE2 binding (p<0.05), but COVID+ plasma inhibited binding to a much greater degree (P<0.001 vs control plasma and no plasma). F) Same data as in A expressed as % inhibition vs. the no-plasma control average. An arbitrary cut-off of 85% inhibition captures all IgG-positive COVID samples. P<0.001. G) Compared to a no-plasma control (blue), pre-COVID control plasma slightly and non-significantly inhibited RBD-ACE2 binding. COVID+ plasma inhibited in some samples, such that the group mean was significantly different from both pre-COVID and no plasma controls (P<0.005 vs control plasma and p<0.01 vs no plasma). However, the population appeared to bifurcate into a responder and non-responder population (dotted line at MFI = 20,000). H) Same data as in C expressed as % inhibition vs the no-plasma control average. P<0.005. I) Trimer MFI plotted vs. % inhibition on the Trimer-Ace2 inhibition assay for all COVID+ samples. J) RBD MFI plotted vs. % inhibition on the RBD-Ace2 inhibition assay for all COVID+ samples. K) % inhibition on the trimer-Ace2 inhibition assay on MagBeads plotted vs. the same assay run on CML beads, for the 12 individuals that were run on both assay types. L) % inhibition on the RBD-Ace2 inhibition assay on MagBeads plotted vs. the same assay run on CML beads, for the 12 individuals that were run on both assay types.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint Figure 1 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

WHO Declares COVID-19 a Pandemic

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Antibody responses to SARS-CoV-2 in patients with COVID-19

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

A human monoclonal antibody blocking SARS-CoV-2 infection

IP-FCM Measures Physiologic Protein-Protein Interactions Modulated by Signal Transduction and Small-Molecule Drug Inhibition

A serological assay to detect SARS-CoV-2 seroconversion in humans

COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions

Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China

Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates

The authors thank Jason McLellan and Barney Graham for their generous gift of the SARS-CoV-2 recombinant trimer and hACE2 expression constructs; Lee Nelson of the Fred Hutchinson Cancer Research Center for providing negative control samples; Julia Gust for technical assistance; the scientists and support staff at SCRI who enabled COVID research to All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 11, 2020.

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint Figure 3 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint Figure S1 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint Figure S2 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.09.20127050 doi: medRxiv preprint